by Shuai Li, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo
Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
The Breast: Open
Access: Published: October 14, 2020
Co-expression of human epidermal growth factor receptor-2
(HER2) and hormone receptor (HR) predicted worse prognosis in early breast
cancer before trastuzumab was developed. We aimed to investigate whether HER2
positivity was still associated with worse outcome in high-risk estrogen
receptor (ER) positive patients treated with trastuzumab and chemotherapy. In
the present study, 227 ER+/HER2+ patients treated with trastuzumab and
chemotherapy (HER2-pos-T group) and 1097 ER+/HER2-patients treated with chemotherapy
alone (HER2-neg group) during 2009 and 2015 were retrospectively enrolled for
the comparison of disease-free survival (DFS) and overall survival (OS).
